세계 PARP 억제제 시장 규모는 예측 기간 동안 13.31%의 CAGR로 성장하여 2023년 64억 4,000만 달러에서 2031년 175억 달러로 성장할 것으로 예상됩니다.
R&D 활동에 대한 투자 증가와 암 유병률 증가는 시장에 유리한 성장 기회를 제공하고 있습니다.
암 유병률 증가로 인해 PARP 억제제의 효능 개선에 대한 관심이 높아지면서 시장 확대에 힘을 실어주고 있습니다. 미국암협회에 따르면, 2023년 미국에서 195만 8,310명의 암 환자가 새로 발생하고 60만 9,820명이 암으로 사망할 것으로 추정됩니다.
National Breast Cancer Foundation에 따르면, 여성 8명 중 1명이 유방암 진단을 받고, 2023년에는 여성 297,790명, 남성 2,800명이 침윤성 유방암 진단을 받을 것으로 추정됩니다. PARP 억제제는 암세포가 손상된 종양 DNA를 복구하는 것을 억제합니다. 올라파립은 조기 유방암과 전이성 유방암 치료에 사용되며, 타라조파립은 전이성 유방암 치료에 사용됩니다.
지역별로는 북미가 가장 큰 시장 점유율을 차지할 것으로 예상됩니다. 이 지역의 주요 기업의 존재, 숙련된 인력의 가용성, 의료 부문을 강화하기 위한 정부 이니셔티브의 증가, 연구 기관과 시장 진입자 모두의 R&D 활동에 대한 투자 증가가 북미 PARP 억제제 시장의 성장을 뒷받침하고 있습니다. 또한, 미국의 다양한 규제 기관은 새로운 암 치료제의 효과에 대한 연구와 승인에 초점을 맞추고 있습니다.
세계 PARP 억제제 시장을 조사했으며, 시장 정의와 개요, 시장 규모 추이와 예측, 각종 부문별·지역별 상세 분석, 산업 구조, 시장 성장에 영향을 미치는 요인 분석, 사례 연구, 경쟁 상황, 주요 기업 개요 등의 정보를 정리하여 전해드립니다.
Global PARP inhibitors market is projected to witness a CAGR of 13.31% during the forecast period 2024-2031, growing from USD 6.44 billion in 2023 to USD 17.5 billion in 2031F. Increased investments in research and development activities and the increasing prevalence of cancer are providing lucrative growth opportunities to the market.
Poly (ADP-ribose) polymerase (PARPs) catalyze the transfer of ADP-ribose in proteins. PARP1 and PARP2 mediate the DNA repair process and play an essential role in maintaining genomic stability. PARP inhibitors prevent cancer cells from repairing, causing their death. These drugs mostly avoid affecting healthy cells and target cancer cells.
The PARP enzyme has a wide range of functions in a cell, such as DNA damage response, regulation of transcription, and apoptosis. PARP inhibitors exploit the concept of synthetic lethality. In this lethal phenomenon, cell can survive an isolated genetic event, whereas cell death occurs in the case of co-occurrence of multiple genetic events. They target cancer cells that have a defective homologous recombination DNA repair pathway.
The growing emphasis on enhancing the efficacy of PARP inhibitors owing to the increasing prevalence of cancer further supports the market expansion. According to American Cancer Society, in 2023, 1,958,310 new cancer cases and 609,820 cancer related deaths were estimated to occur in the United States. The American Cancer Society estimated that in 2024, 12,740 women are expected to die due to ovarian cancer, and 19,680 new cases will be diagnosed in the United States.
Rising Cases of Breast Cancer Boost Market Demand
As per National Breast Cancer Foundation, one out of eight women will be diagnosed with breast cancer over the course of their lifetime. It was estimated that in 2023, 297,790 women and 2,800 men will get a diagnosis of invasive breast cancer. PARP inhibitors prevent the cancer cells from repairing damaged tumor DNA. Olaparib is used for the treatment of both early and metastatic breast cancer, and Talazoparib is used for the treatment of metastatic breast cancer.
Due to the growing prevalence of the disease, various organizations are providing additional funding to research institutions for better treatments and better prediction models for breast cancer. For instance, In November 2023, researchers from University of Washington, Seattle Children's Cancer Consortium and Fred Hutchinson received additional funding from Breast Cancer Research Foundation (BCRF) to continue working on their ongoing studies. The Vice President for Clinical Affairs and a medical oncologist, Davidson received funding for another year to research the expanded applications of PARP inhibitors.
Increasing Research Activities Support the PARP Inhibitors Market Growth
PARP inhibitors have shown promising results since their clinical applications and were the first clinically approved drugs that were developed based on synthetic lethality. The inhibitors have been approved for use as maintenance treatment for cancer patients with BRCA mutations. The continuation of innovative explorations is expected to support the development of potent drugs with novel mechanisms.
In 2023, the American Society of Clinical Oncology (ASCO) presented new updates on the utilization of PARP inhibitors for the treatment of ovarian cancer. Significant attempts are being made to combine PARP inhibitors with immune checkpoint inhibitors (ICIs) in patients suffering from advanced ovarian cancer. It was demonstrated in the DUO-O trial that the addition of maintenance Olaparib and anti-programmed death-ligand 1 (PD-L1) immune checkpoint inhibitor durvalumab to the standard of care prolongs progression free survival in cases on advanced ovarian cancer. PARP inhibitors present a promising avenue in the therapy for ovarian cancer. Ongoing research and development activities for novel agent combinations hold promise for future advancements.
North America Expected to Account for a Significant Market Share
The strong presence of various key players in the region, availability of skilled workforce, increasing government initiatives to strengthen the healthcare sector, and rising investments towards research and development activities by both research institutions and market players is supporting the expansion of the North America PARP inhibitors market. According to American Cancer Society, in 2023, 1,958,310 new cancer cases and 609,820 cancer related deaths were estimated to occur in the United States. Due to the surge in cases of cancer in the region, the requirement for advanced cancer therapeutics, including PARP inhibitors is increasing. The different regulatory bodies in the country are focusing on studying the effects of novel cancer treatments and granting them approvals.
In 2023, Pfizer, Inc., one of the leading pharmaceutical and biotechnology corporations in the United States, announced positive results from their phase 3 TALAPRO-2 study of TALZENNA (Talazoparib), an oral PARP inhibitor, combined with enzalutamide. They demonstrated a clinically meaningful and statistically significant improvement in radiographic progression free survival, with or without HRR gene mutations. The United States Food and Drug Administration (FDA) granted priority review of TALZENNA combined with enzalutamide for treatment of men with metastatic castration-resistant prostate cancer.
Preference for Olaparib Anticipated to Increase
Increasing adoption of Olaparib PARP inhibitors for treatment of pancreatic cancer, ovarian cancer, and both metastatic and early breast cancer is facilitating the market growth. In 2022, an article published in Cancer Discovery discussed the 5-year analysis of data, showing that the patients that received Olaparib for 2 years had a median progression free survival of 3.5 years longer than those who received placebo.
In January 2024, the post-hoc analysis of phase 3 PROpel trial (NCT03732820) presented at the 2024 Genitourinary Cancers Symposium confirmed that the treatment with frontline Olaparib and abiraterone acetate benefits patients with HRR mutated metastatic castration-resistant prostate cancer. The post-hoc exploratory analysis that examined the aggregate subgroups of non-BRCA-mutated, BRCA-mutate, non-HRR-mutated, and HRR-mutated disease further demonstrated favorable radiographic progression free survival outcomes with abiraterone plus Olaparib as opposed to abiraterone alone.
Retail Pharmacies Expected to Witness Significant Growth
The provision of branded as well as generic drugs, with other pharmaceutical products under one roof is bolstering the popularity of retail pharmacies in various regions across the globe. The pharmacists in these pharmacies are trusted counsel by many and often explain the side effects of different drugs to their customers. These pharmacies are an integral component of the healthcare ecosystem in various countries across the globe, accounting for a significant PARP inhibitors market share.
Meanwhile, online pharmacies are expected to rapidly expand in the coming years. The growth can be attributed to providing various benefits by online pharmacies, including privacy, discounts, fast shipping, delivery, convenience, and others. The online purchase of medicines from verified and legitimate internet pharmacies has become an accepted practice among various developed countries.
Future Market Scenario (2024 - 2031F)
Various clinical trials are underway to investigate the next generation of PARP inhibitors. PARP enzymes play different roles at different cell cycle stages, therefore, it is essential to understand the interaction network in the cells for the exploration of novel potential therapies.
Additional studies are required for determining if alternating drug combinations, including PARP inhibitors, anti-angiogenic agents, and immunotherapy are able to offer clinical benefits to patients suffering from ovarian cancer.
Recently, in RUBY Part 2 Phase 3 trial it was noted that the combination of Zejula (niraparib) and Jemperli (dostarlimab) significantly improved progression-free survival in recurrent or primary advanced endometrial cancer. The results have reinforced the development approach of using Jemperli in immuno-oncology-based combination therapies.
Key Players Landscape and Outlook
Key participants in global PARP inhibitors market include Pfizer, Inc., GlaxoSmithKline Plc., Genentech, Inc., AbbVie Inc., and Sierra Oncology, Inc. The rising investments towards research and development activities and increasing prevalence of different types of cancer is providing lucrative growth opportunities to the market.
In 2023, FDA approved Pfizer drug, Talazoparib (Talzenna) with enzalutamide for HRR gene mutated metastatic castration-resistant prostate cancer. The efficacy of the drug was evaluated in a multi-cohort, randomized, placebo-controlled, and double-blind trial that enrolled 399 patients with homologous recombination repair gene mutated metastatic castration-resistant prostate cancer.
All segments will be provided for all regions and countries covered
Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work